Zentalis Pharmaceuticals Inc expected to post a loss of $1.02 a share - Earnings Preview

Zentalis Pharmaceuticals

01/05/2023 14:19

* Zentalis Pharmaceuticals Inc  ZNTL.OQ   ZNTL.O  is
expected
to show no change in quarterly revenue when it reports 
results on May 3 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Zentalis
Pharmaceuticals
Inc is for a loss of $1.02 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 11 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Zentalis
Pharmaceuticals Inc is $48​, above​ its last closing price
of $22.03. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -1.01       -1.06      -0.92     Beat    13.2
 Sep. 30 2022  -1.15       -1.17      -0.96     Beat    17.9
 Jun. 30 2022  -1.18       -1.19      -1.34     Missed  -13​
 Mar. 31 2022  -1.21       -1.21      -1.31     Missed  -7.8
 ​​Dec.        -1.45       -1.49      -1.11     Beat    25.8
 31 2021                                                
 Sep. 30 2021  -1.31       -1.31      -1.25     Beat    4.6​
 Jun. 30 2021  -1.17       -1.17      -1.34     Missed  -14.4
 Mar. 31 2021  -0.97       -0.97      -1.24     Missed  -28.1
 This summary was machine generated May 1 at 13:19 GMT.  All
figures in US dollars  unless otherwise stated